IWM
SPRO icon

IHT Wealth Management’s Spero Therapeutics SPRO Stock Holding History

IHT Wealth Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,090
Closed -$113K – 768
2020
Q3 		$113K Hold
10,090
– – 0.01% 626
2020
Q2 		$137K Sell
10,090
-10,085
-50% -$113K 0.02% 543
2020
Q1 		$163K Buy
20,175
+2,660
+15% +$23.4K 0.02% 493
2019
Q4 		$168K Sell
17,515
-1,000
-5% -$10.8K 0.02% 580
2019
Q3 		$196K Sell
18,515
-200
-1% -$2.11K 0.03% 556
2019
Q2 		$215K Hold
18,715
– – 0.03% 477
2019
Q1 		$240K Hold
18,715
– – 0.04% 414
2018
Q4 		$115K Buy
+18,715
New +$152K 0.02% 450

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVAX
Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

IHT Wealth Management's SPRO Position: Q4 2020 in Review

IHT Wealth Management sold out of Spero Therapeutics (SPRO) in Q4 2020, closing a stake of 10,090 shares — an estimated $113K sold.

IHT Wealth Management first reported a position in SPRO in Q4 2018 and held it in 8 quarters. The position peaked at $240K in Q1 2019. 89 funds tracked by Wall St. Rank hold SPRO as of Q4 2020.

  • IHT Wealth Management reported no remaining Spero Therapeutics position as of Q4 2020 after selling out during the quarter.
  • IHT Wealth Management sold 10,090 Spero Therapeutics shares in Q4 2020, an estimated $113K.
  • IHT Wealth Management first reported a position in Spero Therapeutics in Q4 2018 and held it in 8 quarters.
  • IHT Wealth Management's Spero Therapeutics position peaked at $240K in Q1 2019.
  • 89 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2020.

Based on IHT Wealth Management's 13F filing for Q4 2020, filed 17 Feb 2021.